Company Overview
Clover Health Investments, Corp. operates within the healthcare sector, specifically focusing on the healthcare plans industry where it delivers Medicare Advantage plans to eligible individuals across the United States. The company's operational model involves providing preferred provider organization and health maintenance organization plans, alongside its Clover Assistant software platform designed to assist physicians in detection and identification tasks. This entity represents a mid-sized player in the market with a total market capitalization of $954.89 million and an annual revenue generated over the trailing twelve months of $1.92 billion. With a workforce of 724 employees, the company's scale indicates a significant operational footprint that supports substantial revenue generation relative to its employee count. The valuation suggests a company that has achieved notable revenue expansion but maintains a market cap that reflects specific investor sentiment regarding its profitability trajectory and future growth potential within the competitive Medicare Advantage landscape.
Financial Health
Over the trailing twelve months, Clover Health Investments, Corp. reported revenue of $1.92 billion, yet recorded a net income of $-85,549,000 and an EBITDA of $-85,343,000, highlighting a substantial gap between top-line growth and bottom-line profitability. The discrepancy between the $1.92 billion in revenue and the negative net income reveals a cost structure where operating expenses and losses significantly outweigh gross profits before interest and taxes. The company's free cash flow stands at $-35,821,624, which indicates a current lack of financial flexibility as the business is burning cash rather than generating it from its core operations. Profitability is further illustrated by the three distinct margin metrics: a gross margin of 18.5%, an operating margin of -10.1%, and a profit margin of -4.4%. The negative operating and profit margins confirm that the company is currently operating at a loss on an operational basis, while the positive gross margin suggests that the cost of goods sold remains below the revenue generated from services. On the balance sheet, the company holds $120.26 million in cash while debt data is not available, and the debt-to-equity ratio is listed as N/A, suggesting a capital structure that relies heavily on equity or does not disclose traditional long-term leverage in standard reporting. The current ratio of 1.47 indicates that the company possesses sufficient current assets to cover its short-term liabilities, pointing to a manageable short-term liquidity position despite the cash burn. Finally, the return on equity is -26.3% and the return on assets is -9.5%, metrics that reveal that management is currently generating negative returns on the capital invested and the total assets utilized, reflecting the challenges associated with scaling a loss-making business model.
Valuation Assessment
Valuation metrics for Clover Health Investments, Corp. show a trailing P/E ratio of N/A due to the lack of positive net income, while the forward P/E is 20.22, implying that the market is pricing in expected future earnings growth that could potentially turn the company profitable. The price-to-book ratio stands at 3.06, indicating that the stock is trading at a significant premium relative to its tangible book value, which often suggests investor optimism regarding intangible assets or future recoveries. Alternative valuation measures include a price-to-sales ratio of 0.50 and an EV/EBITDA of -9.78, which suggest that the company is valued based on revenue multiples rather than earnings, a common practice for growth-stage companies with negative earnings. The stock price has fluctuated within a 52-week range defined by a high of $3.92 and a low of $1.78, placing the current valuation context within this historical band where the price sits below the recent high but above the year-low. The beta value of 2.24 indicates that the stock exhibits high price volatility, moving more than twice as much as the broader market, which reflects the heightened risk profile associated with a small-cap healthcare company with negative earnings.
Growth & Income
The company demonstrates robust revenue expansion with a year-over-year revenue growth rate of 44.7%, while earnings growth is listed as N/A due to the absence of recent positive earnings, indicating that revenue expansion is occurring without immediate profitability. Because the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders and instead retains all capital for reinvestment into its business operations and potential future growth initiatives. This non-dividend status aligns with the company's current financial reality where negative returns on equity necessitate the retention of capital to cover operational deficits and fund expansion. The overall growth and income profile is characterized by rapid top-line scaling of nearly 45% annually, coupled with a complete absence of dividend income and negative earnings, presenting a high-risk, high-growth scenario where shareholder returns are dependent entirely on future operational success rather than current cash distributions.